Institutional Investor Sentiment About Puma Biotechnology Inc (NASDAQ:PBYI) Improved

July 18, 2017 - By Nellie Frank

 Institutional Investor Sentiment About Puma Biotechnology Inc (NASDAQ:PBYI)  Improved

Sentiment for Puma Biotechnology Inc (NASDAQ:PBYI)

Puma Biotechnology Inc (NASDAQ:PBYI) institutional sentiment decreased to 1.32 in Q4 2016. Its down -0.17, from 1.49 in 2016Q3. The ratio is negative, as 75 investment professionals increased and started new holdings, while 57 decreased and sold their stakes in Puma Biotechnology Inc. The investment professionals in our partner’s database now possess: 34.24 million shares, up from 29.40 million shares in 2016Q3. Also, the number of investment professionals holding Puma Biotechnology Inc in their top 10 holdings decreased from 2 to 1 for a decrease of 1. Sold All: 36 Reduced: 21 Increased: 53 New Position: 22.

Puma Biotechnology, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The company has market cap of $3.06 billion. The Firm focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 ), PB272 (neratinib (intravenous)) and PB357. It currently has negative earnings. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

About 131,228 shares traded. Puma Biotechnology Inc (NASDAQ:PBYI) has risen 23.65% since July 18, 2016 and is uptrending. It has outperformed by 6.95% the S&P500.

Redmile Group Llc holds 3.41% of its portfolio in Puma Biotechnology Inc for 1.29 million shares. Partner Fund Management L.P. owns 1.14 million shares or 0.99% of their US portfolio. Moreover, Weatherbie Capital Llc has 0.98% invested in the company for 253,802 shares. The New York-based Orbimed Advisors Llc has invested 0.89% in the stock. Partner Investment Management L.P., a California-based fund reported 18,293 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 9 insider sales for $158.24 million activity.

More notable recent Puma Biotechnology Inc (NASDAQ:PBYI) news were published by: Seekingalpha.com which released: “Puma Stalks Up” on July 03, 2017, also Benzinga.com with their article: “Puma Biotechnology Boosted After FDA Approves Breast Cancer Therapy” published on July 18, 2017, Seekingalpha.com published: “Puma’s FDA Decider And Semaglutide’s Head-To-Head Battle” on July 07, 2017. More interesting news about Puma Biotechnology Inc (NASDAQ:PBYI) were released by: Businesswire.com and their article: “Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III …” published on July 06, 2017 as well as Streetinsider.com‘s news article titled: “Puma Biotech’s (PBYI) Neratinib Receives FDA Approval for Extended Adjuvant …” with publication date: July 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.